A review of response in neoadjuvant therapy for exocrine pancreatic cancer

2021 ◽  
Vol 123 (6) ◽  
pp. 1449-1459
Author(s):  
Dominic J. Vitello ◽  
David J. Bentrem
Keyword(s):  
Pancreatic Cancer ◽  
Neoadjuvant Therapy ◽  
Exocrine Pancreatic Cancer

Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy

2021 ◽  
Author(s):  
Asanka R. Wijetunga ◽  
Terence C. Chua ◽  
Christopher B. Nahm ◽  
Nick Pavlakis ◽  
Stephen Clarke ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Neoadjuvant Therapy ◽  
Locally Advanced ◽  
Advanced Pancreatic Cancer ◽  
Locally Advanced Pancreatic Cancer ◽  
Borderline Resectable

scholarly journals The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change?

2021 ◽  
Vol 28 ◽  
pp. 124-128
Author(s):  
Jeffrey M. Ryckman ◽  
Bradley N. Reames ◽  
Kelsey A. Klute ◽  
William A. Hall ◽  
Michael J. Baine ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Neoadjuvant Therapy ◽  
Stereotactic Radiotherapy

scholarly journals Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma—Who Will Benefit from a Secondary Resection?

Medicina ◽  
2021 ◽  
Vol 57 (1) ◽  
pp. 77
Author(s):  
Nathalie Rosumeck ◽  
Lea Timmermann ◽  
Fritz Klein ◽  
Marcus Bahra ◽  
Sebastian Stintzig ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Overall Survival ◽  
Neoadjuvant Therapy ◽  
Induction Therapy ◽  
Locally Advanced ◽  
Eastern Cooperative Oncology Group ◽  
Advanced Pancreatic Cancer ◽  
Comprehensive Cancer Center ◽  
Secondary Resection ◽  
Number Of Patients

Background and Objectives: An increasing number of patients (pts) with locally advanced pancreatic cancer (LAPC) are treated with an intensive neoadjuvant therapy to obtain a secondary curative resection. Only a certain number of patients benefit from this intention. The aim of this investigation was to identify prognostic factors which may predict a benefit for secondary resection. Materials and Methods: Survival time and clinicopathological data of pts with pancreatic cancer were prospective and consecutively collected in our Comprehensive Cancer Center Database. For this investigation, we screened for pts with primarily unresectable pancreatic cancer who underwent a secondary resection after receiving induction therapy in the time between March 2017 and May 2019. Results: 40 pts had a sufficient database to carry out a reliable analysis. The carbohydrate-antigen 19-9 (CA 19-9) level of the pts treated with induction therapy decreased by 44.7% from 4358.3 U/mL to 138.5 U/mL (p = 0.001). The local cancer extension was significantly reduced (p < 0.001), and the Eastern Cooperative Oncology Group (ECOG) performance status was lowered (p = 0.03). The median overall survival (mOS) was 20 months (95% CI: 17.2–22.9). Pts who showed a normal CA 19-9 level (<37 U/mL) at diagnosis and after neoadjuvant therapy or had a Body Mass Index (BMI) below 25 kg/m2 after chemotherapy had a significant prolonged overall survival (29 vs. 19 months, p = 0.02; 26 vs. 18 months, p = 0.04; 15 vs. 24 months, p = 0.01). Pts who still presented elevated CA 19-9 levels >400 U/mL after induction therapy did not profit from a secondary resection (24 vs. 7 months, p < 0.001). Nodal negativity as well as the performance of an adjuvant therapy lead to better mOS (25 vs. 15 months, p = 0.003; 10 vs. 25 months, p < 0.001). Conclusion: The pts in our investigation had different benefits from the multimodal treatment. We identified the CA 19-9 level at time of diagnosis and after neoadjuvant therapy as well as the preoperative BMI as predictive factors for overall survival. Furthermore, diagnostics of presurgical nodal status should gain more importance as nodal negativity is associated with better outcome.

The continuing challenge of exocrine pancreatic cancer

1999 ◽  
Vol 25 (6-7) ◽  
pp. 360-365 ◽  
Author(s):  
T. R. Worthington ◽  
R. C. N. Williamson
Keyword(s):  
Pancreatic Cancer ◽  
Exocrine Pancreatic Cancer

Machine learning-based auto-segmentation of histological residual tumor in resected pancreatic cancer after neoadjuvant therapy

Pancreatology ◽  
2021 ◽  
Vol 21 ◽  
pp. S90
Author(s):  
B. Janssen ◽  
R. Theijse ◽  
S. van Roessel ◽  
R. de Ruiter ◽  
A. Berkel ◽  
...  
Keyword(s):  
Machine Learning ◽  
Pancreatic Cancer ◽  
Neoadjuvant Therapy ◽  
Residual Tumor

Molecular biology of exocrine pancreatic cancer

2006 ◽  
Vol 8 (5) ◽  
pp. 306-312 ◽  
Author(s):  
José Luis Soto ◽  
Víctor Manuel Barbera ◽  
Miguel Saceda ◽  
Alfredo Carrato
Keyword(s):  
Pancreatic Cancer ◽  
Molecular Biology ◽  
Exocrine Pancreatic Cancer

Lifetime History of Tobacco Consumption and K-ras Mutations in Exocrine Pancreatic Cancer

Pancreas ◽  
2007 ◽  
Vol 35 (2) ◽  
pp. 135-141 ◽  
Author(s):  
Marta Crous-Bou ◽  
Miquel Porta ◽  
Tom??s L??pez ◽  
Manuel Jariod ◽  
N??ria Malats ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Tobacco Consumption ◽  
Ras Mutations ◽  
Lifetime History ◽  
History Of ◽  
Exocrine Pancreatic Cancer

scholarly journals Neoadjuvant Therapy of Pancreatic Cancer: The Emerging Paradigm?

2012 ◽  
Vol 17 (2) ◽  
pp. 192-200 ◽  
Author(s):  
Kian‐Huat Lim ◽  
Eugene Chung ◽  
Adeel Khan ◽  
Dengfeng Cao ◽  
David Linehan ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Neoadjuvant Therapy
Sign in / Sign up

Export Citation Format

Share Document